CEBP CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fung, W. L. A.
Right arrow Articles by Narod, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fung, W. L. A.
Right arrow Articles by Narod, S. A.
Cancer Epidemiology Biomarkers & Prevention Vol. 12, 678-680, July 2003
© 2003 American Association for Cancer Research


Short Communications

The N314D Polymorphism of Galactose-1-Phosphate Uridyl Transferase Does Not Modify the Risk of Ovarian Cancer

W. L. Alan Fung, Harvey Risch, John McLaughlin, Barry Rosen, David Cole, Danny Vesprini and Steven A. Narod1

The Center for Research in Women’s Health, University of Toronto, Toronto, Ontario, M5G 1N8 Canada [W. L. A. F., D. V., S. A. N.]; Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06510-8034 [H. R.]; The Samuel Lunenfeld Research Institute, M5G1X5 Toronto, Ontario, Canada [J. M.]; Department of Gynecology, Toronto Hospital, M5G2M9 Toronto, Ontario, Canada [B. R.]; and Department of Clinical Biochemistry, University of Toronto, M5G1L5 Toronto, Ontario, Canada [D. C.]

It has been proposed that high levels of galactose consumption increase the risk of ovarian cancer. Galactose levels are determined, in part, by the galactose-1-phosphate uridyl transferase gene (GALT). The N314D allele of the GALT gene has been associated with low GALT activity and with an increased risk of ovarian cancer. We screened for the presence of the N314D GALT allele in 891 incident cases of epithelial ovarian cancer and in 364 unaffected female controls. No significant difference in the prevalence of the N314D allele was observed between the cases (18.1%) and the controls (18.7%). The odds ratio associated with the presence of one N314D allele was 0.94 (95% confidence interval (CI), 0.68–1.3; P = 0.70), and the odds ratio associated with two N314D alleles was 1.62 (95% CI, 0.34–7.7; P = 0.54). Subanalyses of the cases by histological type, by age, by ethnic group, by family history, and by BRCA1/2 mutation status did not reveal any significant associations. We conclude that the GALT N314D allele does not predispose to epithelial ovarian cancer.




This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
T. Forges, P. Monnier-Barbarino, B. Leheup, and P. Jouvet
Pathophysiology of impaired ovarian function in galactosaemia
Hum. Reprod. Update, September 1, 2006; 12(5): 573 - 584.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2003 by the American Association for Cancer Research.